Jejunal Adenocarcinoma Case Study: Callie
With surgery and FidoCure® therapy, Callie is alive and well almost 20 months after her initial diagnosis of jejunal adenocarcinoma.
Osteosarcoma Case Study: Jade
With a combination approach that included FidoCure® therapy, Jade is alive and well 2 years after her initial diagnosis of osteosarcoma.
Insulinoma Case Study: Winston
With a combination approach that included FidoCure®, Winston survived two years following his initial diagnosis of metastatic insulinoma.
FidoCure® Precision Medicine Data Showcased at the American Association of Cancer Research (AACR)
At the AACR 2023 annual meeting, Dr. Lucas Rodrigues, Head of Veterinary Research at FidoCure®, presented the results of two innovative studies which demonstrated the power of real-world data from dogs with cancer to drive drug development strategies and inform human clinical trials.
The first study, titled "High frequency of TP53 mutations in canine skin tumors recapitulates solar induced human lesions representing an important research model of spontaneous diseases," focused on the similarities between skin tumors in dogs and humans caused by sun exposure. The study found a high frequency of TP53 mutations in canine skin tumors, mirroring those seen in humans with solar-induced skin lesions. This validates the use of dogs as a valuable research model for spontaneous diseases.
Thrive Pet Healthcare and FidoCure® Announce An Expansive Pet Precision Health Partnership
Strategic partnership leveraging FidoCure’s precision medicine platform advances joint vision for providing personalized, accessible veterinary cancer care
Get to Know: Chase Schwalbach, Chief Product Officer, FidoCure
Tell us about your background
I grew up on the Ohio/Kentucky border, from a relatively modest background. My mom worked 3 jobs to support me and my 2 siblings, and I...
World Veterinary Day Interview: Strengthening Veterinary Resilience
Resilience is defined as the capacity to recover quickly from difficulties and toughness-- there are both physical and psychological resilience. Both have been severely tested these last few years with the pandemic, the current war, national divisions, etc. and have really affected veterinarians in the world at large.
Rising Women in Veterinary Oncology
An introduction from Chief Medical Officer, Dr. Gerry Post
Veterinary medicine is changing. I remember one of my first days in veterinary school looking at the class pictures that were hung in the hallways. I remember seeing the first woman in one of these class photos and noting that she was still practicing.
Medical Brief: PIK3CA and KRAS Mutations Predict for Response to Everolimus Therapy
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001 Morassa Mohseni, Ben Ho Park J Clin Invest. 2010;120(8):2655-2658. https://doi.org/10.1172/JCI44026.
